This study compares the production of recombinant AAV vectors using traditional plasmid DNA and neDNA™, a linear DNA molecule free of bacterial sequences. Evaluating both methods in Viralgen’s Pro10™ cell line across various AAV serotypes and scales, we assess vector potency in vivo, offering insights into safer and more efficient AAV manufacturing approaches.
